Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

In an Imperfect World: Strategies for Psychiatric Clinical Trials


Studies involving psychiatry drugs may be uniquely challenging.

Tweetables from this article:

Tweet: Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. http://ctt.ec/lf2Zz+ Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study.

Share this!

September 16, 2016 | by Megan Sims

In a perfect world, clinical drug trials draw conclusive results from objective observations. But we don’t live in that world, and we doubt you do, either.

Studies involving psychiatry drugs may be uniquely challenging. Ensuring that trial data accurately captures a compound’s safety and efficacy potential requires that you account for challenges inherent in working with a mentally ill population. Observing changes in the disease under study is partly a subjective process, and that creates risk of undue influence that the patient and/or investigator may not recognize.

To further complicate things, not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. Some changes may result from unrelated factors whose therapeutic effect erodes the efficacy signal of a potential treatment.

On Tuesday, September 20, join two experts from Premier Research for a revealing look at these challenges. Krista Armstrong, Vice President of Strategic Development, and Susan Kozauer, Senior Medical Director, will present Conclusive Results: Strategies for Collecting Quality Data in Psychiatric Clinical Trials. The hour-long session, beginning at 11 a.m. Eastern time, will explore a range of factors that — if identified and mitigated early in the development process — can maximize the potential for conclusive study results. Look for a particular focus on:

  • Study design considerations
  • Site factors
  • Subject selection and eligibility
  • Data surveillance

The neuroscience experts at Premier Research have performed more than 150 neuroscience studies in just the past five years, their work touching more than 27,000 patients afflicted with all major central nervous system disorders. Register today for what is sure to be an informative presentation.

Keywords: Premier Research, Psychiatry, Clinical Trials



        Share this with your colleagues!

        The Top 4 Most Expensive Drugs in the US are Hepatitis C Treatments

        July 28, 2017 - In recognition of World Hepatitis Day, let’s take a look at the modern treatments capable of curing patients with hepatitis C.

        Manufacturing Top 5 Most Impactful Tweets from #AAIC17

        July 21, 2017 - This week, we’ll be rounding up 5 of the most impactful tweets from the Alzheimer’s Association International Conference (AAIC) held in London, England this year. The AAIC is the largest international conference dedicated to furthering Alzheimer’s disease and dementia research, uniting researchers from more than 70 countries across the globe. Here are the highlights from the research presented at the AAIC to keep you in the loop.

        Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

        July 17, 2017 - Once implemented, a manufacturing control strategy is not only beneficial for pharmaceutical companies to help them avoid product launch delays and quality concerns; patients benefit greatly from being able to rely upon the quality and increased production efficiency of drug products.


        6 Tips to Overcome Nervousness When Speaking in a Webinar


        Data Integrity and the Manufacturing Control Strategy for Life Sciences Manufacturers

        Biosimilar Development: Lessons Learned from Early Clinical Studies

        Understanding Medical Device Regulatory Pathways in China and Japan

        Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned

        Copyright © 2016-2017 Honeycomb Worldwide Inc.